Fitch Ratings backs J&J move to sell Ortho Clinical Dx arm; Covidien declares quarterly cash dividend;

@FierceMedDev: Boston Scientific won't begin its U.S. hypertension study until it reviews Medtronic's setback. More | Follow @FierceMedDev

@MarkHFierce: Google is developing a contact lens that monitors glucose levels. Partners needed to bring the product to market. Story | Follow @MarkHFierce

@MichaelGFierce: Study: Carotid stents, regardless of origin, are similarly effective at preventing stroke, death. Item | Follow @MichaelGFierce

@EmilyWFierce: Flu season predictions from scientists at Columbia could help you stay out of bed. Article | Follow @EmilyWFierce

@GalenMoore: Here's who was in the room when a team from Google X met with FDA officials last month. | Follow @GalenMoore

> Fitch Ratings said it supported plans by Johnson & Johnson ($JNJ) to sell its Ortho Clinical Diagnostics arm to Carlyle Group for $4.15B, calling it a "strategically sound" move to unload a division with lower opportunities for long-term growth. Item

> Sweden's Aerocrine inked an exclusive deal with Healthcare 21 to sell, market and distribute Aerocrine's new airway inflammation monitor and test kit across the U.K. and Ireland. Item

> Covidien ($COV) has declared a quarterly cash dividend of 32 cents per share. Item

> Sequenom ($SQNM) said that France's Nicox will have exclusive rights to market its RenaGene laboratory-developed test for age-related macular degeneration in the U.S. Item

> Illumina ($ILMN) unveiled a new system that it says can produce full human DNA sequencing at $1,000 per genome. Story

Biotech News

@FierceBiotech: Auspex's $76M IPO pitch tests the limits of biotech's window. Story | Follow @FierceBiotech

@JohnCFierce: ICYMI: Roche 's dealmakers at pRED will continue their global shopping spree in 2014. Piece | Follow @JohnCFierce

@DamianFierce: Welcome back, Ariad: Iclusig returns after a cold winter. More | Follow @DamianFierce

@EmilyMFierce: Experimental microparticle therapy could treat inflammatory conditions, from effects of heart attack to diabetes. Article | Follow @EmilyMFierce

> Prosensa heralds new hope for once-failed muscular dystrophy drug. More

> Shire takes an L on Dermagraft, unloads it to Organogenesis. Story

> ArQule rides high on good news for its never-say-die cancer drug. News

Pharma News

@FiercePharma: Big Pharma accused of hatching 'satanic plot' in South Africa. More | Follow @FiercePharma

@TracyStaton: Trending at FiercePharma: Novartis may finally face generic competition for Diovan. Yesterday's story | Follow @TracyStaton

@EricPFierce: FDA investigator assigned to Europol to fight fakes being hawked online by drug rings. Story from FiercePharmaManufacturing | Follow @EricPFierce

@CarlyHFierce: ICYMI: Look for Teva's new chief to move fast on dealmaking, CFO says. Story | Follow @CarlyHFierce

> FDA advisory panel gives J&J's Xarelto resounding 'no' for ACS. Story

> Roche resolves shortage of liquid Tamiflu. Article

> Gilead's Sovaldi rolls on with approval in EU. Item

Suggested Articles

Qiagen launched a one-stop shop compiling publicly available genomic data, scientific literature and phenotypic information on potential superbugs.

Adaptive Biotechnologies is planning a $200 million IPO to help power its sequencing tests aimed at the body’s immune system and related therapies.

Abbott’s new diabetes test provides A1c results in three minutes, allowing clinicians to develop care plans within a single office visit.